Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by MineDiggeron Jun 15, 2022 3:21am
144 Views
Post# 34757159

RE:(TSXV:BTI.V; OTCQB:BIOAF): 4th Quarter/YE Statements

RE:(TSXV:BTI.V; OTCQB:BIOAF): 4th Quarter/YE StatementsI see no new positive information in the MD&A (YE to 2022-02-28), have I missed anything? No obvious comment about any ongoing collaborations, but I haven't read every word. It is said "no news is good news" wrt Bioasis I disagree. In fact, they’ve even fallen out with two partners it seems “two contract dispute matters". Is it possible our valuable know-how is being stolen by one or two of the so-called partners? Or did Bioasis screw up? Or what?
 
No cash: "its existing cash balance is sufficient to fund operation through approximately July 2022" There is mention of $7m remaining of the Lind $10m , but nothing said about intending to use it.

Next to no income, just $38k in Q3: "The increase in research revenue of $37,725 from YTD Q4 2021 to YTD Q4 2022, is due to a new material transfer agreement with a global pharmaceutical company in Q3 2022, as compared to an absence of new material agreements in YTD Q4 2021.". Whatever that was it isn’t worth investigating.


As I said, didn’t read every word and I haven’t finished my first espresso, but I’m not seeing any new positives, at all.
 

MD



<< Previous
Bullboard Posts
Next >>